Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025 17:30 ET  | Source: Fulcrum Therapeutics, Inc. ― Clear…
Wynn Officially Commences the Third Edition of the Wynn Signature Chinese Wine Awards 2026
Wynn continues to pave the way for a more robust future for…
CITES Praises India’s Vantara for Exemplary Wildlife Care and Full Compliance with Global Standards
DUBAI, UAE, Nov. 13, 2025 /PRNewswire/ -- In a significant acknowledgment for…
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and…
Cango Inc. Releases Letter to Shareholders
HONG KONG, Nov. 6, 2025 /PRNewswire/ -- Cango Inc. (NYSE: CANG) today…
Senores Pharma Reports Strong Q2 & H1 FY26 Performance, Sustains Growth Momentum Across Businesses
AHMEDABAD, India, Nov. 7, 2025 /PRNewswire/ --Â Senores Pharmaceuticals Limited continued its strong…
Kia Announces 2025 Third Quarter Business Results
Kia posts Q3 revenue of KRW 28.69 trillion, up 8.2% Y/yQ3 global…
Indigenously Designed and Manufactured Laptops by Vyonix Launched at IMC 2025
GURUGRAM, India, Oct. 27, 2025 /PRNewswire/ -- India's 1st indigenously designed and…
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT…
SANY Earns Dual Global Honors for Employer Excellence and Brand Strength
BEIJING, Oct. 16, 2025 /PRNewswire/ -- With its continued focus on employee…